Who Paid My Doc
Michael Moriarty
Adolescent Medicine Wethersfield, CT Doctor of Osteopathy
NPI 1881075372 CMS profile 1357545
1025 Silas Deane Hwy, Wethersfield, CT 06109
General payments
$83
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Michael Moriarty of Wethersfield, CT is reported in the CMS Open Payments database as having received $83 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26 | 1 | |
| 2023 | General | $20 | 1 | |
| 2019 | General | $37 | 2 |
Beside peers
- Michael Moriarty
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Michael Moriarty were reported at $26. Among 40 Adolescent Medicine profiles paid that year, the median was $135 and the middle half received between $78 and $573.
Show as a table
| Year | Michael Moriarty | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $37 | $112 | $24–$444 | $163 |
| 2020 | $0 | $80 | $35–$250 | $114 |
| 2021 | $0 | $229 | $55–$448 | $132 |
| 2022 | $0 | $162 | $35–$492 | $149 |
| 2023 | $20 | $182 | $54–$507 | $160 |
| 2024 | $0 | $142 | $59–$362 | $164 |
| 2025 | $26 | $135 | $78–$573 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 115 drugsPart D claims
6,234
Drug cost
$528,709
Branded share of claims
18.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 92 | $111,488 | |
| Eliquis Apixaban | Brand | 76 | $97,865 | |
| Januvia Sitagliptin Phosphate | Brand | 72 | $91,120 | |
| Jardiance Empagliflozin | Brand | 37 | $56,192 | |
| Trulicity Dulaglutide | Brand | 25 | $24,042 | |
| Xarelto Rivaroxaban | Brand | 23 | $16,970 | |
| Farxiga Dapagliflozin Propanediol | Brand | 15 | $16,052 | |
| Mounjaro Tirzepatide | Brand | 14 | $15,076 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 14 | $14,550 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 48 | $7,985 |
The 10 drugs with the highest cost, of 115 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 37 billing codesPaid by Medicare
$45,074
Medicare patients
171
Services billed
950
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 39% | |
| Diabetes | 29% | |
| Ischemic heart disease | 28% | |
| Chronic kidney disease | 22% | |
| Depression | 21% | |
| Heart failure | 20% | |
| Atrial fibrillation | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 18 | 18 | $1,473 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Adolescent Medicine in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.